Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01076361 · ClinicalTrials.gov registry record
Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study
A clinical trial, sponsored by Medtronic.
- Completed
- Registry status
- 370
- Enrollment target
NCT01076361: Completed study, sponsored by Medtronic.
NCT01076361 is a clinical trial that has completed, run by Medtronic. The registered enrollment target is 370 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01076361 has completed, sponsored by Medtronic.
- COMPLETED
- Registry status
- 370 participants
- Enrollment target
Study Summary
The Medtronic CapSure Epi Lead Post-approval Study will assess long-term safety of the 4968 lead. This study is part of the Medtronic System Longevity Study.
Primary Outcome
The survival analysis takes into account: Enrolled participants, lead follow-up time, and adjudicated lead related complications. The life-table method was used to analyze lead survival probability.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 1999-09 |
| Est. Completion | 2010-09 |
What the finished NCT01076361 record still lists
NCT01076361 is an observational study that tracks outcomes without assigning an intervention. The registered 370 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01076361 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01076361 about?
NCT01076361 is a clinical study titled "Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study". The Medtronic CapSure Epi Lead Post-approval Study will assess long-term safety of the 4968 lead. This study is part of the Medtronic System Longevity Study.
What is the current status of trial NCT01076361?
This trial is currently completed. The enrollment target is 370 participants. The study started on 1999-09. Estimated completion is 2010-09.
Who is sponsoring clinical trial NCT01076361?
This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- NCT04284436 · 370 participants · NA
Study in Parkinson Disease of Exercise
- NCT05026749 · 370 participants · Phase 3
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- NCT05125016 · 370 participants · Phase 1
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia